Business Description
NewAmsterdam Pharma Co NV
NAICS : 325412
SIC : 2834
ISIN : NL00150012L7
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 766.38 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 15.77 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -198.4 | |||||
3-Year EPS without NRI Growth Rate | -189.1 | |||||
3-Year FCF Growth Rate | -167.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 9.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 88.14 | |||||
9-Day RSI | 80.24 | |||||
14-Day RSI | 72.88 | |||||
6-1 Month Momentum % | -21.31 | |||||
12-1 Month Momentum % | 123.26 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.83 | |||||
Quick Ratio | 9.83 | |||||
Cash Ratio | 9.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | -11.15 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2880.08 | |||||
Net Margin % | -3607.99 | |||||
FCF Margin % | -2963.24 | |||||
ROE % | -34.34 | |||||
ROA % | -29.6 | |||||
ROIC % | -205.57 | |||||
ROC (Joel Greenblatt) % | -36865.04 | |||||
ROCE % | -26.54 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 475 | |||||
PB Ratio | 4.41 | |||||
Price-to-Tangible-Book | 4.64 | |||||
EV-to-EBIT | -12.21 | |||||
EV-to-Forward-EBIT | -7.99 | |||||
EV-to-EBITDA | -12.22 | |||||
EV-to-Revenue | 351.78 | |||||
EV-to-Forward-Revenue | 517.82 | |||||
EV-to-FCF | -11.86 | |||||
Price-to-Net-Current-Asset-Value | 4.64 | |||||
Price-to-Net-Cash | 4.82 | |||||
Earnings Yield (Greenblatt) % | -8.19 | |||||
FCF Yield % | -6.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
NewAmsterdam Pharma Co NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 3.406 | ||
EPS (TTM) (€) | -2.411 | ||
Beta | 0 | ||
Volatility % | 96.81 | ||
14-Day RSI | 72.88 | ||
14-Day ATR (€) | 0.720582 | ||
20-Day SMA (€) | 15.055 | ||
12-1 Month Momentum % | 123.26 | ||
52-Week Range (€) | 5.4 - 22.8 | ||
Shares Outstanding (Mil) | 90.02 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NewAmsterdam Pharma Co NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NewAmsterdam Pharma Co NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
NewAmsterdam Pharma Co NV Frequently Asked Questions
What is NewAmsterdam Pharma Co NV(FRA:KH6)'s stock price today?
When is next earnings date of NewAmsterdam Pharma Co NV(FRA:KH6)?
Does NewAmsterdam Pharma Co NV(FRA:KH6) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |